1. American Cancer Society. For Women Facing a Breast Biopsy. http://www.cancer.org/docroot/CRI/content/CRI_2_4_6x_For_Women_Facing_a_Breast_Biopsy.asp?sitearea=, 2008.
2. Wood WC, Muss HB, Solin LJ, Olopade OI. Chapter 33, Section 2: Malignant tumors of the breast. In Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principals and Practice of Oncology, 7th edition. Philadelphia: Lippincott Williams & Wilkins, 2005.
3. Evers K. Chapter 16: Image-guided biopsy of nonpalpable breast lesions, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
4. Youk JH, Kim EK, Kim MJ, Oh KK. Sonographically guided 14-gauge core needle biopsy of breast masses: a review of 2,420 cases with long-term follow-up. AJR Am J Roentgenol. 190(1):202-7, 2008.
5. Bleicher RJ. Chapter 5: Management of the palpable breast mass, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
6. Chang JC, Hilsenbeck SG. Chapter 31: Prognostic and Predictive Markers, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
7. Surowiak P, Materna V, Györffy B, et al. Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer. 95(3):339-46, 2006.
8. Grube BJ, Giuliano AE. Chapter 41: Sentinel lymph node dissection, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
9. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 349:546-53, 2003.
10. Radovanovic Z, Golubovic A, Plzak A, et al. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer. Eur J Surg Oncol. 30(9):913-7, 2004.
11. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Cancer. 106(1):4-16, 2006.
12. Xing Y, Foy M, Cox DD, et al. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 93(5):539-46, 2006.
13. Krag DN, Anderson SJ, Julian TB, et al. for the National Surgical Adjuvant Breast and Bowel Project Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8(10):881-8, 2007.
14. Zavagno G, De Salvo GL, Scalco G, et al. for the GIVOM Trialists. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg. 247(2):207-13, 2008.
15. Gill G for the SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol. 16(2):266-75, 2009.
16. Nixon AJ, Schnitt SJ, Gelman R, et al. Relationship of tumor grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breast-conserving therapy. Cancer. 78:1426-31, 1996.
17. Dillon DA, Guidi AJ, Schnitt SJ. Chapter 28: Pathology of Invasive Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
18. Hansen NM. Chapter 66: Paget’s Disease, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
19. Merajver SD, Iniesta MD, Sabel MS. Chapter 62: Inflammatory Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
20. Bentzon N, Düring M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer. 122(5):1089-94, 2008.
21. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 295(21):2492-2502, 2006.
22. Wiseman SM, Makretsov N, Nielsen TO, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103(9):1770-7, 2005.
23. Ries LAG, Eisner MP and Kosary CL. SEER Cancer Statistics Review, 1973-1998, National Cancer Institute. http://seer.cancer.gov/csr/1973_1998/, 2001.
24. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 30;351(27):2817-26, 2004.
25. Genomic Health, Inc. Oncotype Dx: Breast cancer assay. http://www.oncotypedx.com/ / Redwood City, CA. 2009.
26. DeMartini W, Lehman C, Partridge S. Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol. 15(4):408-16, 2008.
27. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J. 11(3):204-9, 2005.
28. National Human Genome Research Institute NIoH. DNA Microarray Technology. www.genome.gov/pfv.cfm?pageid=10000533, 2009.
29. Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist. 13(4):350-60, 2008.
30. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
31. Budd GT, Cristofanelli M, Ellis MJ, Stopeck A, et al. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer. Clin Cancer Res. 12(21):6403-9, 2006.
32. Cristofanelli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer. 7(6):471-9, 2007.
33. De Giorgi U, Valero V, Rohren E , et al. Circulating tumor cells and [18F] fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 27(20):3303-11, 2009.
34. Harris L, Fritsche H, Mennel R, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 25(33):5287-312, 2007.
35. Ignatiadis M, Kallergi G, Ntoulia M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 14(9):2593-600, 2008.
36. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 26(8):1208-15, 2008.
37. National Cancer Data Base, American Cancer Society. Detailed guide: Breast cancer. American College of Surgeons and American Cancer Society, 2005.
38. American Cancer Society. Breast Cancer Facts & Figures 2009-2010, 2009.
39. Harper S, Lynch J, Meersman SC, et al. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev. 18(1):121-31, 2009.
40. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control. 20(4):417-35, 2009.
41. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev. 18(1):121-31, 2009.
42. Rose DP and Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev. 25:16-31, 2001.
43. Jones BA, Kasl SV, Howe CL, et al. African-American/White differences in breast carcinoma: p53 alteration and other tumor characteristics. Cancer. 101:1293-301, 2004.
44. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst. 97(6):439-48, 2005.
45. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 14(10):2994-3003, 2007.
46. Dawood S, Broglio K, Kau SW, et al. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 27(2):220-6, 2009.
47. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res. 10(4):R67, 2008.
48. Hannemann J, Kristel P, van Tinteren H, et al. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer. 95(10):1334-41, 2006.
49. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 355(6):560-9, 2006.
50. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology. 69(6):478-85, 2005.
51. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 16(3):439-43, 2007.
52. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109(1):123-139, 2008.
53. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101(10):736-50, 2009.
54. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 7:96, 2006.
55. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 8(4):R34, 2006.
56. Millar EK, Graham PH, O'Toole SA, et al. Prediction of Local Recurrence, Distant Metastases, and Death After Breast-Conserving Therapy in Early-Stage Invasive Breast Cancer Using a Five-Biomarker Panel. J Clin Oncol. 27(28):4701-8, 2009.
57. Yehiely F, Moyano JV, Evans JR, Nielsen TO, Cryns VL. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 12(11):537-44, 2006.
58. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 25(43):5846-53, 2006.
59. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 26(26):4282-8, 2008.
60. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 37(9):1217-26, 2006.
61. Bowen RL, Duffy SW, Ryan DA, Hart IR, Jones JL. Early onset of breast cancer in a group of British black women. Br J Cancer. 98(2):277-81, 2008.
62. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 113(2):357-70, 2009.
Updated 10/26/09
